Related Experiment Video

Updated: Aug 8, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

[Celecoxib in NSAID-induced cutaneous and respiratory adverse reactions]

Antonio Valero1, Ernesto Enrique, Miquel Baltasar

  • 1Servicio de Neumología y Alergia Respiratoria. Hospital Clínic. Barcelona. Spain. cpicado@medicina.ub.es

Medicina Clinica
|December 4, 2003
PubMed
Abstract

Insights

Most patients intolerant to non-steroidal anti-inflammatory drugs (NSAIDs) tolerated celecoxib, a specific COX-2 inhibitor. This suggests celecoxib is a safe alternative for pain and inflammation relief in NSAIDs-sensitive individuals.

Area of Science:

  • Pharmacology
  • Immunology
  • Gastroenterology

Background:

  • Non-steroidal anti-inflammatory drugs (NSAIDs) commonly cause adverse reactions due to cyclooxygenase-1 (COX-1) inhibition.
  • Cyclooxygenase-2 (COX-2) selective inhibitors may offer an alternative with a reduced side effect profile.

Purpose of the Study:

  • To evaluate the tolerance of celecoxib, a selective COX-2 inhibitor, in patients with a history of NSAIDs intolerance.
  • To determine if celecoxib can be a safe therapeutic option for NSAIDs-sensitive individuals.

Main Methods:

  • A single-blind study was conducted involving NSAIDs-intolerant patients.
  • Patients were challenged with placebo and escalating doses of celecoxib up to 400 mg.

Main Results:

  • The study included 59 NSAIDs-intolerant patients, with common reactions including urticaria and bronchospasm.
  • Only 3.4% of patients (2 out of 59) experienced urticaria when treated with celecoxib.

Conclusions:

  • Celecoxib demonstrates good tolerability in the majority of patients who are intolerant to traditional NSAIDs.
  • Celecoxib represents a potentially safe and effective alternative for managing pain and inflammation in NSAIDs-sensitive populations.

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

Related Concept Videos

Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...